Special Pre-Conference Tutorial Maximizing Pipeline Value Know Your Market and Fail Fast 8:00 Pre-Conference Tutorial Registration and Continental Breakfast 8:30 Chairperson's Welcome and Introduction: Letting Attrition Happen When it Should Dr. Samuel Holtzman, President and CEO, Rosa Pharmaceuticals What considerations should lead to attrition decisions? Key organizational and economic forces that severely delay attrition Aligning the organization to carry out attrition decisions 8:45 Making Tough Attrition Decisions ... and Making them Stick Dr. David Stewart, Director of Technology Licensing and Alliances, Aventis SA 9:30 Fail Fast or Fail Forever...the View from Biotech Dr. Alan Dunton, President and CEO, MetaPhore Pharmaceuticals, Inc. (former President, Janssen Research Foundation, and Group Vice President, R. W. Johnson Pharmaceutical Research Institute) 10:15 Refreshment Break 10:30 Moderated Panel and Audience Discussion 11:15 Concluding Remarks 11:30 End of Pre-Conference Tutorial

Co-sponsoring Publications: WHO SHOULD ATTEND? This Executive Forum is designed especially for Senior and Mid-level Managers whose responsibilities involve one or more of the following: Drug Discovery Drug Development Project Management Project Planning Process Management Informatics Operations Strategic Planning Information Technology Knowledge Management Data Management Clinical Operations Technology Licensing Portfolio Management Decision Analysis

11:45 Main Conference Registration

12:45 OPENING KEYNOTE PRESENTATIONProductivity

Challenge Facing Big Pharma Osagie O. Imasogie, Vice President & Director of Genetics and Discovery, GSK Ventures, GlaxoSmithKline There is a perceived, and some would say real, productivity challenge facing big pharmaceutical companies. Homegrown drug portfolios are shrinking, and the biggest companies are using in-licensing of compounds and acquisitions of smaller companies to maintain a strong pipeline. Why is this? Why is our R&D spending increasing and the number of prospective new blockbusters so dramatically decreasing? During this talk, I will discuss how real this productivity gap is and offer my perspective on possible approaches to managing.

1:30 Chairperson's Opening Remarks
Dr. Vanessa R. Lum, Director, Decision Analysis & Portfolio Management, Johnson & Johnson Pharmaceutical Research & Development

1:45 Optimizing and Prioritizing R&D Projects within the Pharmaceutical Portfolio
Dr. Richard Heaslip, Vice President, Project Management, Wyeth Research

• Defining projects and the factors that determine their value

• Implementing processes to validate and analyze the data

• Utilizing the data for project optimization and portfolio assessments

• Identifying metrics to measure success

2:30 Strategies for Optimizing R&D Processes after a Merger or Acquisition
Dr. Vanessa R. Lum

Mergers & acquisitions continue to shape the competitive landscape of the pharmaceutical industry. Expanded operational capabilities should make R&D more productive, however, often the result is just the opposite. What have we learned about how to configure R&D operations to realize the forecasted value of merged product pipelines?

• Defining the vision and model for consolidated R&D operations

• Optimizing development process in parallel with cultural change management

• Establishing post-merger R&D governance

3:15 Networking Refreshment Break

3:45 Knowledge Sharing and Decision Making in Research - How to Make New Processes and Technologies Work Dr. Rainer Fuchs, Vice President of Research Informatics, Biogen Inc.
Discuss how Biogen introduced new processes for research project management and capability investments and how we made them work Look at the problems of sharing knowledge and information across the organization, and how cultural and technical hurdles can be overcome Learn how information technology was used to improve existing business processes - some real examples

4:30 Integrating Basic Science & Clinical Information Technology to Improve the Drug Discovery Process
John Murphy, Vice President & Chief Information Officer, CuraGenCorporation

• Automation of basic science R&D, expanding beyond UHTS and encompassing all biological processes: Scientist + Computer + Basic Science

• Computerization of the drug discovery process and the seamless integration of clinical medicine and patients into early-stage drug R&D

• Approaches to automate biology-based drug discovery

• Methods used to link physicians and patients into the process in real-time

5:15 Close of Day One

7:30 Continental Breakfast

8:00 Chairperson's Remarks
Dr. Michael Liebman, Computational Biology, Abramson Cancer Center of the University of Pennsylvania

8:10 Modeling and Simulation of Information Flows in Drug Discovery
Dr. Otto Ritter, Associate Director of Bioinformatics, AstraZeneca R&D

• Re-using informatics framework for molecular interactions and pathways

• Constructing and mining models of work processes and information flows within drug discovery

• Integrating information on scientific evidence, technological feasibility and business expectations

• Optimizing the drug discovery portfolio

8:55 Addressing Technology Bottlenecks in the Drug Development Process
Dr. Michael Liebman

• Are the bottlenecks due to technology or science issues?

• Are they being correctly identified and evaluated?

• Are there technology solutions that already exist?

• How do we implement or develop solutions?

• What are the potential benefits and risks involved in fixing the problem?

9:40 Knowledge Management Technologies as Tools in R&D
Jack Pollard, Principal Investigator, 3rd Millennium Inc.

• Knowledge management technologies in R&D

• Choosing the right technology to address the right challenge

• Overcoming implementation hurdles

10:25 Networking Refreshment Break

10:45 Optimizing Information Technology for Clinical Trials Charles Jaffe, MD, PhD, Director of Medical Informatics, AstraZeneca Pharmaceuticals
Streamlining clinical data acquisition Enhancing colocation of data resources Improving time and accuracy of query resolution management Easing adoption of Federal regulations and guidances Speeding time to data lock and FDA submission

11:30 Extracting Knowledge from Information to Lead to Better Decision Making
Dr. Frank Wang, Associate Director, Informatics R&D, Boehringer Ingelheim

• Create optimal value through a balanced IT hardware/software portfolio in support of Pharma R&D

• Develop strategic cross-silo informatics projects in support of new pharma R&D paradigms (chemical biology, toxicogenomics)

• Integrate and distribute R&D data acquisition and analytics (informatics intranet, enterprise portal, data mart)

• Deep and wide data-mining (free text analysis, bio/chemical modeling)

• Capture and disseminate decision-making dynamics (collaborative/KM technology).

1:30 Evaluating the Business Value of R&D Informatics
Dr. Christine Humblet, Executive Director Discovery Research Informatics, Pfizer Global Research Development

• Define the IT project portfolio

• Prioritize the projects for best alignment to business strategies and optimal return of investment

• Evolve partnership between IT and the business lines to manage the IT project portfolio

• Measure against successful impact

2:15 AFTERNOON KEYNOTE PRESENTATION Impact of Technology and Process on R&D Productivity: Are We Making Better Decisions? Dr. Nader Fotouhi, Vice President, Discovery Chemistry, Hoffmann-La Roche

The economic pressures placed on the pharmaceutical industry to generate new chemical entities have resulted in a drive to shorten drug discovery cycle times and reduce cost. The pressure is further increased by the fact that we need to pick the right targets out of the large number of possibilities being provided through the Genomics effort. The increasing number of potential targets that may lead to novel therapeutics necessitates a more parallel approach in lead identification, lead optimization, and candidate selection. Ultra-high throughput screening, virtual screening, high throughput technologies, predictive technologies, and reduction of vast amounts of data to knowledge to drive decision making are all playing a role in increasing the odds in the drug discovery process. The question is, is this enough?

3:00 Leveraging Technology for Better R&D Decisions
Sven Blumenstiel, Principal Consultant, IBM Business Consulting Services
Information technology is recognized as a key productivity tool, yet despite success in other information-driven industries, the pharmaceutical industry has not realized the true strategic potential today's technology offers for improved decision making. Reasons may include the complexity and scientific tradition of pharmaceutical R&D, as well as the industry's reliance on traditional technologies.
Still, the industry has a number of prominent examples where technology has made a profound impact on decision making and generated significant business value. Consequently, the interest in decision support systems that play a central role in the transition to a rational and adaptive drug development approach is rising. However, while technology can play an important enabling role, organizational changes (process & behavior), have to be an integral part for sustainable value generation and improved decision making from pharmaceutical information.
3:45 Networking Refreshment Break

4:05 Six Critical Success Factors in R&D Decision Making
Arjun Bedi, Partner, Global Pharmaceuticals & Medical Products, Accenture
Decision making is the #1 issue affecting R&D performance, according to several senior R&D leaders who participated in a recent Accenture-sponsored forum on R&D productivity. Given the current situation, improving decision making is a major priority of many R&D organizations. We will discuss six elements that are fundamental to effective decision making in pharmaceutical R&D based on our experience with top companies in the industry.
Our research and work in this area demonstrates that the tight integration of these six elements is critical to achieve effective decision making. We will illustrate our point of view using both industry data as well as our own research study results.

5:45 Close of Conference

CHI offers a variety of conference sponsorships designed to bring your company face to face with key executive decision-makers, position your solutions/services and increase revenue opportunities in a highly competitive marketplace. You will interact with Vice Presidents, Heads of Departments and Directors of Biotechnology and Biopharmaceutical companies, who will attend this focused executive forum. For details, please contact: For sponsorship and exhibit information, please contact: Arnie Wolfson at 617- 630-1331; email: awolfson@healthtech.com Angela Parsons at 781-972-5467; email: aparsons@healthtech.com

Hotel Information
Wyndham Philadelphia Hotel
12th and Race Streets
Philadelphia, PA 19103
T: 215-448-2000F: 215-448-2864
Room Rate: $169.00/S $189/D
Cut-off Date: May 19, 2003

Please call the hotel directly to make your room reservation. Identify yourself as a Cambridge Healthtech Institute conference attendee to receive the reduced room rate. Reservations made after the cut-off date or after the group room block has been filled (whichever comes first) will be accepted on a space-and-rate-availability basis. Rooms are limited, so please book early.

PHARMACEUTICAL STRATEGY SERIES (PSS)
For more information about these other PSS Events, please visit: www.pharmaseries.com

• R&D Strategies: Managing Risk to Increase Value
• Optimize R&D Performance
• Strategic Resource Allocation
• Marketing Targets and Compounds
• Recognize Attrition Earlier

Register Online

PDF Version (184k)

Upcoming Conferences

Request info

Order CD

Press pass